Back to Search
Start Over
Familial Chylomicronemia Syndrome Market Expected to Experience Major Growth by 2034, According to DelveInsight | Ionis Pharma, Novartis, Akcea Therapeutics, Arrowhead Pharma, Visirna Therapeutics
- Source :
- M2 Presswire. November 19, 2024
- Publication Year :
- 2024
-
Abstract
- M2 PRESSWIRE-November 19, 2024-: Familial Chylomicronemia Syndrome Market Expected to Experience Major Growth by 2034, According to DelveInsight | Ionis Pharma, Novartis, Akcea Therapeutics, Arrowhead Pharma, Visirna Therapeutics (C)1994-2024 M2 [...]
- Subjects :
- Arrowhead Pharmaceuticals Inc. -- Forecasts and trends
Novartis AG -- Forecasts and trends
BCG vaccines -- Growth -- Forecasts and trends -- Reports
BCG -- Growth -- Forecasts and trends -- Reports
Epidemiology -- Forecasts and trends -- Reports
Pharmaceutical industry -- Forecasts and trends
Company growth
Market trend/market analysis
Business
Business, international
Subjects
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- M2 Presswire
- Publication Type :
- News
- Accession number :
- edsgcl.816682942